Publications
Publications
Show Results For
- All HBS Web
(1,280)
- Faculty Publications (513)
Page 1 of 513
Results →
- November 2024
- Teaching Note
Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams
By: Debora L. Spar and Julia M. Comeau
Teaching Note for HBS Case No. 323-039. In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At... View Details
- October 2024
- Case
Lanco Medical Group: Fostering Happiness for Growth
By: Susanna Gallani, Jenyfeer Martínez Buitrago and Katherine Sonnefeldt
This case describes how Lanco Medical Group, a fast-growing pharmaceutical distributor serving Latin America, approached the design of their employee benefits and incentives program. After learning about gaps between what leadership believed motivated employees and... View Details
- October 2024
- Case
Parexel: Scaling Up and Industry Dynamics
By: Regina E. Herzlinger and Ben Creo
Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One option... View Details
- August 2024
- Case
Novo Nordisk Foundation
By: Debora L. Spar and Julia Comeau
In 2024, Novo Nordisk A/S was one of the most profitable firms in the world, thanks largely to just two GLP-1-based drugs, Ozempic and Wegovy. Unusually, this incredibly profitable firm was controlled not by individual private shareholders, but by a non-profit... View Details
- August 2024
- Article
How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?
By: Leemore S. Dafny, Kate Ho and Edward Kong
Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by... View Details
- June 2024
- Case
Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital
By: Joshua D. Margolis and Ahmed Dahawy
Lana Ghanem, managing director of Hikma Ventures, the corporate venture arm of larger pharmaceutical group Hikma, is considering how to grow the venture arm as well as progress her own career. Over the past few years Hikma's executive team had been pressuring the... View Details
Keywords: Business Divisions; Corporate Entrepreneurship; Investment; Corporate Governance; Health Care and Treatment; Leadership Development; Business or Company Management; Growth and Development Strategy; Business Strategy; Venture Capital; Pharmaceutical Industry; Pharmaceutical Industry; Jordan
- June 2024
- Supplement
Legacy Partners (A)
By: Richard S. Ruback and Royce Yudkoff
Instructors should consider the timing of making videos available to students, as they may reveal key case details.
Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021.... View Details
Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021.... View Details
Keywords: Acquisition; Small Business; Cost vs Benefits; Decisions; Corporate Entrepreneurship; Leadership Style; Leading Change; Business or Company Management; Problems and Challenges; Health Care and Treatment; Health Disorders; Medical Specialties; Nutrition; Supply Chain Management; Growth Management; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; California
- 2024
- Working Paper
Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency
By: Mosab Hammoudeh, Joshua Lev Krieger and Jiajie Xu
This paper investigates whether moving R&D from incumbents to startups can increase innovation. Using comprehensive drug development data, we examine the outcomes of drug projects licensed from large firms to startups. We find that these projects licensed to startups... View Details
- 18 Apr 2024
- Lecture
Innovation Opportunities Created by COVID-19 Can Help: And How to Make Them Happen
The crush of patients created by COVID enabled the creation of sites for care outside the traditional hospital, such as retail pharmacies, ambulatory surgery centers, urgent care centers, telemedicine, and wireless sensors. Public policy mirrored these changes by... View Details
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details
Keywords: Cost vs Benefits; Decisions; Judgments; Values and Beliefs; Global Strategy; Health Care and Treatment; Patents; Growth and Development Strategy; Growth Management; Product Positioning; Supply and Industry; Supply Chain; Corporate Social Responsibility and Impact; Mission and Purpose; Philanthropy and Charitable Giving; Opportunities; Social Issues; Equality and Inequality; Pharmaceutical Industry; Pharmaceutical Industry; Denmark; United States; Europe; China; India; Middle East; North Africa
- March 2024 (Revised July 2024)
- Case
WeightWatchers: Promoting Weight Health
In December 2023, the 60-year-old weight management industry stalwart WeightWatchers announced the launch of WeightWatchers Clinic, which incorporated GLP-1s , a new class of prescription weight-loss medications, into the company’s portfolio of products and mobile app... View Details
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
- February 2024
- Teaching Note
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul
Teaching Note for HBS Case No. 724-412. View Details
- February 2024
- Article
Representation and Extrapolation: Evidence from Clinical Trials
By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams
This article examines the consequences and causes of low enrollment of Black patients in clinical
trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is
more relevant for decision-making by physicians and patients when it... View Details
- January 2024
- Supplement
Accounting Red Flags or Red Herrings at Catalent? (B)
By: Joseph Pacelli, ZeSean Ali and Tom Quinn
GlassHouse Research identified accounting red flags at Catalent. Fiat Lux Partners countered most of GlassHouse’s claims. Who was right? This update explores the aftermath of the short seller duel. View Details
Keywords: Accounting Audits; Acquisition; Budgets and Budgeting; Business Earnings; Earnings Management; Cost Accounting; Fair Value Accounting; Financial Reporting; Revenue Recognition; Integrated Corporate Reporting; Fairness; Moral Sensibility; Values and Beliefs; Government Legislation; Conflict of Interests; Announcements; Blogs; Debates; Lawsuits and Litigation; Stocks; Performance Productivity; Pharmaceutical Industry; Pharmaceutical Industry; United States
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
- October 2023 (Revised April 2024)
- Case
Accounting Red Flags or Red Herrings at Catalent? (A)
By: Joseph Pacelli, ZeSean Ali and Tom Quinn
Fund manager Janet Curie asked for a recommendation about the pharmaceutical company Catalent. The company seemed like a solid investment. However, a pair of research reports issued over the previous two months complicated this narrative. GlassHouse Research, a short... View Details
Keywords: Accounting Audits; Budgets and Budgeting; Earnings Management; Cost Accounting; Fair Value Accounting; Revenue Recognition; Integrated Corporate Reporting; Fairness; Moral Sensibility; Values and Beliefs; Government Legislation; Conflict of Interests; Announcements; Blogs; Debates; Investment; Trust; Business and Shareholder Relations; Pharmaceutical Industry; Pharmaceutical Industry; United States
- October 2023 (Revised May 2024)
- Case
Thermo Fisher Scientific: Foray into Contract Research
By: Satish Tadikonda, William Marks and Kevin Emancipator
After publicly declaring that they would not enter the contract research organization (CRO) business in 2017, Thermo Fisher purchased Pharmaceutical Product Development (PPD), one of the biggest players in the CRO space, in 2021. Much had changed in the intervening... View Details